Compare Abbott India with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs IPCA LABS - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA IPCA LABS ABBOTT INDIA/
IPCA LABS
 
P/E (TTM) x 57.7 26.9 214.5% View Chart
P/BV x 17.1 5.5 313.0% View Chart
Dividend Yield % 0.4 0.2 181.2%  

Financials

 ABBOTT INDIA   IPCA LABS
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
IPCA LABS
Mar-19
ABBOTT INDIA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs8,8341,042 847.8%   
Low Rs5,458590 924.8%   
Sales per share (Unadj.) Rs1,731.1298.6 579.7%  
Earnings per share (Unadj.) Rs211.935.0 605.5%  
Cash flow per share (Unadj.) Rs219.949.4 444.8%  
Dividends per share (Unadj.) Rs65.003.00 2,166.7%  
Dividend yield (eoy) %0.90.4 247.4%  
Book value per share (Unadj.) Rs945.2247.1 382.5%  
Shares outstanding (eoy) m21.25126.35 16.8%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x4.12.7 151.1%   
Avg P/E ratio x33.723.3 144.6%  
P/CF ratio (eoy) x32.516.5 196.9%  
Price / Book Value ratio x7.63.3 228.9%  
Dividend payout %30.78.6 357.8%   
Avg Mkt Cap Rs m151,848103,108 147.3%   
No. of employees `0003.513.4 25.9%   
Total wages/salary Rs m4,3567,874 55.3%   
Avg. sales/employee Rs Th10,555.52,807.0 376.0%   
Avg. wages/employee Rs Th1,249.9585.8 213.4%   
Avg. net profit/employee Rs Th1,292.2329.0 392.8%   
INCOME DATA
Net Sales Rs m36,78637,732 97.5%  
Other income Rs m1,133577 196.4%   
Total revenues Rs m37,91938,309 99.0%   
Gross profit Rs m6,0476,901 87.6%  
Depreciation Rs m1691,824 9.3%   
Interest Rs m23189 11.9%   
Profit before tax Rs m6,9895,465 127.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,4851,042 238.4%   
Profit after tax Rs m4,5034,422 101.8%  
Gross profit margin %16.418.3 89.9%  
Effective tax rate %35.619.1 186.4%   
Net profit margin %12.211.7 104.5%  
BALANCE SHEET DATA
Current assets Rs m27,61023,778 116.1%   
Current liabilities Rs m8,56910,975 78.1%   
Net working cap to sales %51.833.9 152.6%  
Current ratio x3.22.2 148.7%  
Inventory Days Days60104 58.0%  
Debtors Days Days2766 41.6%  
Net fixed assets Rs m1,05720,368 5.2%   
Share capital Rs m213253 84.1%   
"Free" reserves Rs m19,87330,971 64.2%   
Net worth Rs m20,08631,224 64.3%   
Long term debt Rs m01,409 0.0%   
Total assets Rs m29,40945,507 64.6%  
Interest coverage x311.630.0 1,040.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.30.8 150.9%   
Return on assets %15.410.1 151.9%  
Return on equity %22.414.2 158.3%  
Return on capital %34.917.3 201.5%  
Exports to sales %045.9 0.0%   
Imports to sales %016.6 0.0%   
Exports (fob) Rs mNA17,308 0.0%   
Imports (cif) Rs mNA6,266 0.0%   
Fx inflow Rs m36917,308 2.1%   
Fx outflow Rs m4,9186,266 78.5%   
Net fx Rs m-4,54911,042 -41.2%   
CASH FLOW
From Operations Rs m4,9914,923 101.4%  
From Investments Rs m-2,570-1,563 164.4%  
From Financial Activity Rs m-1,428-1,832 77.9%  
Net Cashflow Rs m9931,528 65.0%  

Share Holding

Indian Promoters % 0.0 45.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 11.4 69.3%  
FIIs % 0.1 25.3 0.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 17.4 98.3%  
Shareholders   18,270 36,892 49.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare ABBOTT INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 143 Points Lower; Realty and Oil & Gas Stocks Witness Selling(Closing)

India share markets recovered some losses during closing hours today and ended their day marginally lower.

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Down 0.3% (Market Updates)

Feb 27, 2020 | Updated on Feb 27, 2020

ABBOTT INDIA share price has hit an all time high at Rs 16,661 (up 0.6%). The BSE HEALTHCARE Index is down by 0.3%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 0.6%) and SANOFI INDIA (up 1.0%). The top losers include AJANTA PHARMA and LAURUS LABS LTD (down 0.1%).

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

Here's Why I Recommended 15 Stocks in One Day Flat(Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

These Rebirth of India Stocks Are Raring to Compete with Tesla(The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 27, 2020 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - PIRAMAL ENTERPRISES COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS